Róbert Wessman founded Alvotech in 2013 with the mission to set a new standard in biosimilars. Wessman’s initial strategy was to invest in the development and manufacture of a portfolio of biosimilar monoclonal antibodies and to build a state-of-the-art manufacturing facility in Reykjavik Iceland.
In its brief history, Alvotech has swiftly established itself as a global leader in biosimilars, developing the highest quality biosimilars and making them accessible to patients around the world for enhanced quality of life.
Róbert Wessman is known for his clear focus and his ability to successfully combine operational efficiency and external growth through strategic acquisitions. A business graduate and former lecturer at the University of Iceland, Róbert Wessman began his career at the Icelandic shipping company.
A business school graduate, Róbert Wessman began his career at the Icelandic shipping company Samskip where he quickly advanced to the post of CEO in Germany. In 1999, he became President and CEO of a small Icelandic company called Delta, which under his leadership became the third largest generic pharmaceutical company in the world known as Actavis.
Róbert Wessman founded a new generic pharmaceutical company Alvogen in 2009. Alvogen has received multiple industry recognition's including CPhI Company of the Year Awards and multiple service awards.
Róbert Wessman’s achievements have made him the subject of three Harvard Business School Case Studies, Robert Wessman and the Actavis Winning Formula, published in May 2008, Alvogen, published in December 2015 and Alvogen – Scaling entrepreneurship, published in August 2018.